UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (19) 19
science & technology (19) 19
humans (18) 18
female (11) 11
male (9) 9
treatment outcome (9) 9
abridged index medicus (7) 7
drug therapy, combination (7) 7
2nd-line treatment (6) 6
aged (6) 6
chemotherapy (6) 6
infectious diseases (6) 6
microbiology (6) 6
hiv (5) 5
hiv infections - drug therapy (5) 5
hiv infections - virology (5) 5
immunology (5) 5
middle aged (5) 5
oncology (5) 5
the impact of hiv drug resistance on the selection of 1st- and 2nd-line art in resource-limited settings (5) 5
adult (4) 4
aids (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
antiretrovirals (4) 4
disease-free survival (4) 4
docetaxel (4) 4
neoplasm staging (4) 4
2nd-line therapy (3) 3
anti-retroviral agents - administration & dosage (3) 3
cancer (3) 3
carcinoma, non-small-cell lung - drug therapy (3) 3
child (3) 3
children (3) 3
double-blind (3) 3
drug resistance (3) 3
drug resistance, viral (3) 3
follow-up studies (3) 3
hiv infections - prevention & control (3) 3
hiv-1 - drug effects (3) 3
hiv-1 - physiology (3) 3
lung neoplasms - drug therapy (3) 3
metastasis (3) 3
pharmacology & pharmacy (3) 3
prognosis (3) 3
review (3) 3
rna, viral - genetics (3) 3
survival rate (3) 3
umcg approved (3) 3
virology (3) 3
2nd line therapy (2) 2
adenine - administration & dosage (2) 2
adenine - analogs & derivatives (2) 2
aged, 80 and over (2) 2
analysis (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antiretroviral drug resistance (2) 2
antiretroviral therapy (2) 2
antirheumatic agents - therapeutic use (2) 2
arts (2) 2
assisted reproductive techniques (2) 2
bevacizumab (2) 2
bevacizumab - therapeutic use (2) 2
breast cancer (2) 2
carcinoma, squamous cell - drug therapy (2) 2
care and treatment (2) 2
cisplatin (2) 2
colorectal neoplasms - drug therapy (2) 2
cost-benefit analysis (2) 2
deoxycytidine - analogs & derivatives (2) 2
developing countries (2) 2
disease risks (2) 2
disease transmission (2) 2
erlotinib (2) 2
evidence-based medicine (2) 2
gemcitabine (2) 2
general & internal medicine (2) 2
genetic mutation (2) 2
growth-factor receptor (2) 2
health aspects (2) 2
health care sciences & services (2) 2
health policy & services (2) 2
hiv infections - transmission (2) 2
hiv-1 - genetics (2) 2
infants (2) 2
infectious disease transmission, vertical - prevention & control (2) 2
irinotecan (2) 2
lung neoplasms - pathology (2) 2
medicine (2) 2
medicine, general & internal (2) 2
metastatic colorectal cancer (2) 2
metastatic renal cell carcinoma (2) 2
mother-to-child transmission (2) 2
mutation (2) 2
mutation, missense (2) 2
neoplasm metastasis (2) 2
neoplasms (2) 2
open-label (2) 2
organophosphonates - administration & dosage (2) 2
oxaliplatin (2) 2
patient compliance (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2009, Volume 27, Issue 12, pp. 2038 - 2045
Purpose We performed a randomized phase II trial comparing pemetrexed with pemetrexed plus carboplatin (PC) in patients experiencing relapse after... 
RHEUMATOID-ARTHRITIS | TRIAL | POLYMORPHISMS | CISPLATIN | METHYLENETETRAHYDROFOLATE REDUCTASE GENE | 2ND-LINE TREATMENT | METHOTREXATE | DOCETAXEL | UMCG Approved | THYMIDYLATE-SYNTHASE | CHEMOTHERAPY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Guanine - analogs & derivatives | Carcinoma, Squamous Cell - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Carcinoma, Large Cell - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Membrane Transport Proteins - genetics | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | gamma-Glutamyl Hydrolase - genetics | Lung Neoplasms - genetics | Pharmacogenetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Carboplatin - administration & dosage | Survival Rate | Treatment Outcome | Adenocarcinoma - drug therapy | Pemetrexed | Thymidylate Synthase - genetics | Adenocarcinoma - secondary | Disease Progression | Reduced Folate Carrier Protein | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Glutamates - administration & dosage | Carcinoma, Squamous Cell - secondary | Polymorphism, Genetic - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Guanine - administration & dosage | Index Medicus
Journal Article
by Petrylak, Daniel P and de Wit, Ronald and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor J and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Chi, Kim Nguyen and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Sarid, David and Scagliotti, Giorgio Vittorio and Bracarda, Sergio and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and Hashine, Katsuyoshi and Inokuchi, Junichi and Yokomizo, Akira and Nagamori, Satoshi and Lee, Hyo Jin and Park, Se Hoon and Rha, Sun Young and ... and RANGE study investigators and RANGE Study Investigators
The Lancet (British edition), ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma... 
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Evidence-based medicine | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2017, Volume 55, pp. 16 - 25
Journal Article